Mesenchymal stem cells promote alveolar epithelial cell wound repair in vitro through distinct migratory and paracrine mechanisms
© Akram et al.; licensee BioMed Central Ltd. 2013
Received: 24 September 2012
Accepted: 22 January 2013
Published: 25 January 2013
Mesenchymal stem cells (MSC) are in clinical trials for widespread indications including musculoskeletal, neurological, cardiac and haematological disorders. Furthermore, MSC can ameliorate pulmonary fibrosis in animal models although mechanisms of action remain unclear. One emerging concept is that MSCs may have paracrine, rather than a functional, roles in lung injury repair and regeneration.
To investigate the paracrine role of human MSC (hMSC) on pulmonary epithelial repair, hMSC-conditioned media (CM) and a selected cohort of hMSC-secretory proteins (identified by LC-MS/MS mass spectrometry) were tested on human type II alveolar epithelial cell line A549 cells (AEC) and primary human small airway epithelial cells (SAEC) using an in vitro scratch wound repair model. A 3D direct-contact wound repair model was further developed to assess the migratory properties of hMSC.
We demonstrate that MSC-CM facilitates AEC and SAEC wound repair in serum-dependent and –independent manners respectively via stimulation of cell migration. We also show that the hMSC secretome contains an array of proteins including Fibronectin, Lumican, Periostin, and IGFBP-7; each capable of influencing AEC and SAEC migration and wound repair stimulation. In addition, hMSC also show a strong migratory response to AEC injury as, supported by the observation of rapid and effective AEC wound gap closure by hMSC in the 3D model.
These findings support the notion for clinical application of hMSCs and/or their secretory factors as a pharmacoregenerative modality for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung disorders.
Bone marrow-derived mesenchymal stem cells are a population of multipotent adult stem cells, distinct from haematopoietic stem cells, that classically can differentiate into mesodermal lineages including osteoblasts, chondrocytes, adipocytes, and cardiomyocytes [1–3]. Numerous reports also suggest differentiation into other, non-mesodermal lineages including neurons [4, 5], hepatocytes  and lung epithelial cells [7–9].
This evidence provides a strong rational for the potential application of hMSCs in regenerative therapeutic approaches in many diseases including those of the lung where effective treatment options may be limited . Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disorder of unknown aetiology and the most common and lethal form of interstitial lung diseases with a post diagnosis median survival time of 3–5 years irrespective of its treatment status . Hypothetically, the pathophysiology of IPF is most likely associated with multiple alveolar injuries, failure or delayed alveolar reepithelialisation, abnormal immune responses and subsequent fibrosis [12–14]. Studies involving the bleomycin-induced pulmonary fibrosis mouse model, a widely used animal model of pulmonary fibrosis , demonstrated the migration and homing of endotracheal or systematically transplanted MSCs towards the site of injury and attenuation of pulmonary fibrosis [16, 17]. However, the magnitude of the amelioration of fibrosis appeared out of proportion to the numbers of engrafted MSCs which had differentiated into alveolar epithelial cells (AECs) indicating the involvement of other mechanisms in this MSC-mediated reparative process. An emerging consensus is that paracrine mechanisms could be associated with MSC-mediated wound repair and tissue regenerative process . However, the identity of these paracrine factors with a putative role in alveolar injury repair and regeneration is not clear.
A wide range of different growth factors, cytokines and extracellular matrix proteins (ECM) have been identified as constituents of the in vitro cultured MSC secretome [19, 20]. Many of these secretory proteins are biologically active with anti-inflammatory, anti-fibrotic and immunomodulatory functions [21, 22]. Previous reports have demonstrated that conditioned media obtained from MSC culture improved cutaneous wound healing [19, 23] and cardiac repair . However, data supporting the role of MSC-secreted paracrine factors in the mediation of AEC wound repair is absent. In this study, we have tested hMSC serum-free conditioned media (CM) on AEC wound repair using an in vitro scratch wound repair assay. We demonstrate that hMSC-CM alone increased AEC migration, contained an array of secretory proteins, but had little impact on the rate of wound repair. However, supplementation of hMSC-CM with trace levels of serum (0.2%) significantly increased both migration and wound repair. A selected cohort of hMSC secretory proteins were tested for their effect on repair of AEC and small airway epithelial cells (SAEC) isolated from small airways of distal human lung, and diverse effects on wound healing and cell migration were noted. By developing a direct contact co-culture wound repair system we also demonstrated that when placed in close proximity, hMSCs would migrate into, and repair, AEC wounds in vitro. These findings provide an insight in understanding the cellular and paracrine effects of hMSC in alveolar wound repair and for possible application of hMSC secretory products or their equivalent recombinant proteins as an alternative pharmacoregenerative therapeutic option for pulmonary fibrosis.
hMSC isolation and cell culture
hMSCs were isolated and expanded from human bone marrow aspirates following previously published methodology [25, 26]. Briefly, human whole bone marrow aspirate (collected from iliac crest) (Lonza, USA) was seeded at a density of 105 mononuclear cells/cm2 on 10 ng/ml Fibronectin-coated (Cat. No. F0895, Sigma) T-75 tissue culture flasks in 20 ml of DMEM (High glucose, 4.5g/L) supplemented with 5% foetal bovine serum (FBS), 1% L-glutamine, 1% non-essential amino acid (NEAA) and 1% PSA (Penicillin-Streptomycin-Amphotericin B) without any prior gradient centrifugation or immunoselection. Cells were maintained in continuous culture for three weeks in a humidified incubator at 37°C in the presence of 5% CO2 and 95% air. After 7 days, half of media was removed and replaced with antibiotic-free medium as described above. Media was replenished after a further week. At the end of third week, the adherent hMSC population was harvested with trypsin and passaged subsequently using 1:4 split ratio for expansion. Passage 1 to 3 cells and their conditioned media were used for all experiments. Human type II alveolar epithelial cell (AEC) line, A549 cells were purchased from ATCC, Rockville, USA and maintained in a continuous culture in DMEM supplemented with 10% FBS, 1% L-glutamine and 1% NEAA and passage 10–45 cells were utilised for wound repair and migration assay. Human primary small airway epithelial cells (SAEC) were purchased from Lonza, USA and cultured following manufacturer instruction using SAGM Bullet Kit (Lonza, USA) complete growth media. SAECs were harvested and passaged using Subculture Reagent Pack (Lonza, USA). Passage 3 to 4 SAECs were used for all experiments. Human normal lung fibroblast cell line CCD-8Lu was purchased from ATCC, Rockville, USA and maintained in a continuous culture (passage 9–14) in DMEM supplemented with 10% FBS, 1% L-glutamine and 1% NEAA. This research did not involve human participants. All cells used in this study were obtained from commercial third party organizations.
Characterisation of hMSCs and AECs
In vitro AEC and SAEC wound repair assay
Internuclear distances between migrated AECs and the cells attached to the wound margins were measured by Image J software. A total 108 measurements were recorded from six individual experiments (Figure 2E and 2F).
To evaluate the effects of MSC-CM and CCD-8Lu CM on AEC proliferation during wound repair, we have performed a set of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay using MTT reagent Thiazolyl Blue Tetrazolium Bromide (Sigma, Cat No- M5655) following manufacturer instructions . Briefly, 105 AEC were grown confluence on each well of 48-well plate in 24 hours and wounds were made as described earlier. For 0 hour reading, MTT was performed just after wounding. Wounded monolayers were washed and 300 μl of 0.5 mg/ml MTT reagent containing SF-DMEM solution was added in each well and incubated at 37°C for 2 hours. After incubation, MTT solution was discarded and washed twice with pre-heated PBS. The formazan was then extracted by 100% DMSO (250 μl/well) incubating 10 minutes in the incubator. 200 μl of extracted formazan-DMSO solution was then loaded in each well of 96-well plate and absorption was measured by micro-plate reader (BioTek, Synergy 2) at 630 nm wavelength. For 24 hours reading, wounded AEC monolayers were treated with SF-MSC CM or 2% FBS supplemented MSC-CM or SF-CCD 8Lu CM or 0.2% FBS supplemented CCD-8Lu CM for 24 hours in the incubator. For negative and positive control, cells were treated with SF-or 0.2% FBS supplemented DMEM and 10% FBS supplemented DMEM respectively. After 24 hours of incubation, media was discarded and MTT was performed as above. Triplicate was done for each sample. Data was presented as percentage increase of optical density (OD) reflecting degree of cell proliferation after 24 hours (Figure 2G, 3B).
AEC-MSC direct-contact co-culture assay
For assessment of hMSC migration to AEC wound sites in AEC-MSC direct-contact co-culture DiO-labelled hMSCs were counted at the AEC wound gaps and their juxta-wound monolayers at 0 and after 24 hours of wounding (Figure 4D). Confocal Z-scanning was performed to confirm the migration (Figure 4B, vertical and horizontal bars). A minimum of three fields were counted per sample.
Secretome analysis by mass spectrometry
For identification of secretory proteins in MSC-CM, serum-free and 0.2% FBS supplemented MSC conditioned media was concentrated (Amicon Centriplus Centrifugal Filter Device, 3 kDa MW cut off; Millipore). Samples were reduced and alkylated with 1 μL of 1M DTT for 1 hour at 45°C and 25 μL of 200 mM iodoacetamide for 30 minutes at room temperature in the dark followed by overnight digestion with porcine sequencing grade trypsin (2 μg per sample, Promega). The digested samples were then separated by liquid chromatography. Peptides were eluted for 40 minutes over a 2%-50% MeCN gradient, followed by further elution for 10 minutes at 90% MeCN. Samples were spotted onto a MALDI plate and analyzed in both MS and MS/MS mode on a 4800 MALDI TOF/TOF (Applied Biosystems). Data was searched against the NCBI nr Human database. Proteins that were matched with >95% total ion score C.I% and more than 2 peptides were considered as significant. MSC-CM from three independent donors were evaluated to identify common proteins.
Testing of proteins on AEC and SAEC wound repair
Collagen drop cell migration assay
The significance of difference between groups was determined by one-way ANOVA with Post-hoc Tukey’s Multiple Comparison analysis. A ‘p’ value less than 0.05 was considered to indicate statistical significant. Data are presented as mean ± standard deviation (SD). All statistical analysis was performed using GraphPad Prism version 5.00 software for Windows (GraphPad Software, San Diego, California, USA).
hMSC secretome stimulates alveolar epithelial cell wound repair in a serum-dependant manner
To investigate the role of the hMSC secretome on AEC and SAEC wound repair, human MSC-derived serum-free conditioned media was tested on proSurfactant protein-C (proSP-C) expressing human type II AEC line A549 (AEC) (Figure 1A) and primary human SAEC utilising an established in vitro scratch wound repair model . A characteristic of idiopathic pulmonary fibrosis is aberrant repair processes in wounded alveolar epithelium resulting in denuded epithelium . The source of these wounds remains unknown but disrupted repair of the alveolar epithelium is the underlying principle. The use of the scratch wound repair model replicates the wounds, and through the controlled experimentation we describe, allows replication of the inability to repair and a platform to test novel factors in repair stimulation. hMSC were isolated from bone marrow aspirates according to previously described methodology [25, 26] and immunophenotype (CD44+, CD90+, CD146+, STRO-1+, CD14-, and CD19-) (Figure 1B) was confirmed prior to experimental use. The multipotency of hMSC was confirmed by differentiation into osteogenesis, adipogenesis and chondrogenesis lineages, confirmed by use of traditional cytological and immunological studies using Alizarin Red/Osteocalcin, Oil Red O/FABP-4 and Alcian Blue/Aggrecan respectively (Figure 1C). hMSC serum-free conditioned media (SF-MSC CMDMEM) did not show any stimulatory effect on AEC wound repair after 24 hours (36.0 ± 9.8% SF-MSC CMDMEM vs. 34.6 ± 6.6% SF-DMEM (negative control)) whereas SAEC wound repair was increased with SF-MSC CMSABM (93.5 ± 7.6% SF-MSC CMSABM vs. 66.8 ± 6.6% SF-SABM (negative control); p < 0.001) (Figure 2A, 2C). Surprisingly, supplementation of SF-MSC CMDMEM with trace amounts of FBS improved the rate of AEC wound repair stimulation when compared with corresponding DMEM controls supplemented with same amounts of FBS (Figure 2B). Maximal effect was observed with the addition of 0.2% FBS in SF-MSC CMDMEM over its corresponding control (0.2% FBS supplemented DMEM) (66.3 ± 7.4% vs. 35.7 ± 9.5%; p < 0.001) (Figures 2B and 2D). The correlation between wound repair rate and increase in FBS addition was poor, though consistent, when FBS concentrations of <1% were examined. This was noted for both SF-MSC CMDMEM and DMEM (Figure 2B).
SF-MSC CMDMEM without additional FBS supplementation did not increase the AEC wound repair rate. However, when exposed to SF-MSC CMDMEM for 24 hours, isolated AECs migrated from their wound margins towards wound gaps with an accompanying migratory morphology (Figure 2E). Inter-nuclear distances, a measure of migration [27, 30], in SF-MSC CMDMEM treated AEC were significantly higher than that observed in SF-DMEM treated wounded AECs (44.6 ± 3.7 μm vs. 30.6 ± 3.0 μm; p < 0.001) (Figure 2F). Next, we investigated the influences of 0.2% FBS supplementation with SF-MSC CMDMEM or SF-DMEM on AEC proliferation during in vitro wound repair. The MTT assay, an established method for determination of cell proliferation, demonstrated that supplementation of SF-MSC CMDMEM or SF-DMEM with 0.2% FBS did not increase AEC proliferation after 24 hours of wound repair; whereas, supplementation of 10% FBS with DMEM significantly increased AEC proliferation in comparison to both SF-DMEM and SF-MSC CMDMEM (p < 0.001) (Figure 2G). Taken together, serum-free MSC conditioned media alone can stimulate migratory behaviour of AEC during attempted wound repair but does not induce AEC wound repair without supplementation of additional trace levels of serum. However, SAEC wound repair required SF-MSC CMSABM only. These findings demonstrate a phenotype-dependant and anatomical compartment-specific diverse paracrine response to hMSC secretome on distal airway and AEC wound repair where, at least for the AEC, the reparative process was accomplished by stimulation of cell migration. On the contrary, serum-free or 0.2% FBS supplemented conditioned media obtained from normal human lung fibroblasts CCD-8Lu (CCD-8Lu CM) neither enhanced AEC wound repair (Figure 3A, 3C) nor stimulated AEC cell proliferation (Figure 3B). This observation suggests a distinct influence of hMSC and normal human lung fibroblasts on alveolar epithelial wound repair.
hMSC migrate into wounded AEC layers in response to injury
hMSC migration to the site of injury is proposed as an important element of AEC wound repair and regeneration in animal models of pulmonary fibrosis . To investigate the migratory properties of hMSC we developed a two-cell co-culture 3D wound repair model (Figure 4A). In response to AEC injury hMSCs migrated into the AEC wound and completely closed the wound gap (Figure 4B and 4C). AEC wound repair was significantly lower in both the negative and positive control than in the AEC-MSC direct contact co-culture (28.0 ± 6.5% (negative control, AEC upper PET membrane surface mono-culture in SF-DMEM), 72.0 ± 6.9% (positive control, AEC upper PET membrane surface mono-culture in 10% FBS DMEM) and 100% (AEC-MSC direct-contact in SF-DMEM) respectively; p < 0.001 vs AEC-MSC direct contact) (Figure 4C). Cell migration assessment demonstrated a 5-fold higher hMSC migration into wound gaps over the juxta-wound monolayers after 24 hours of direct contact co-culture (mean values 308.3 ± 13.9 (wound gap) vs. 66.0 ± 13.4 (juxta-wound margin); p < 0.001) (Figure 4D). In the absence of AEC, hMSC did not migrate to the opposite surface of the porous transwell membrane (data not shown).
Proteins detected in MSC conditioned media show differential wound repair potential
Protein components of SF-MSC CM detected by LC-MS/MS mass spectrometry
Average Peptide count
Fibronectin 1, isoform CRA_j
Collagen alpha-2(I) chain
Collagen alpha 1 chain precursor variant
Pro alpha 1(I) collagen
Alpha 1 (I) chain propeptide
Collagen, type VI, alpha 1 precursor
Precursor polypeptide (AA −31 to 1139)
Actin, gamma 1 propeptide
Tumor necrosis factor
Osteoblast specific factor 2 (Periostin)
Chain A, Crystal Structure Of The Thrombospondin-1
Collagen alpha 1(V) chain precursor
Insulin-like growth factor binding protein 7, isoform CRA_a
Thrombospondin 2 precursor
Fructose-bisphosphate aldolase A
Heparan sulfate proteoglycan
Pigment epithelium-derived factor
Profilin Binds Proline
Protein disulfide isomerase
Versican isoform 3 precursor
The Antigenic Identity Of Peptide(Slash)mhc Complexes
COL1A1 and PDGFB fusion transcript
Peptidylprolyl isomerase A
Similar to cardiac leiomodin
Solution Structure Of Calcium-Calmodulin N-Terminal Domain
Myosin, light chain 6, alkali, smooth muscle and non-muscle isoform 1
Protein disulfide-isomerase A3
Insulin-like growth factor binding protein 6
Fibronectin and Lumican but not Periostin stimulate AEC migration as substrate components
Fibronectin, Lumican and Periostin induced AEC wound repair when delivered as a culture medium supplement. As these proteins are abundant within the ECM, we hypothesised that these proteins could influence AEC migration as substrate components. Immediate relevance to fibrotic lung disease is evidenced by the abrogation of effective AEC migration over denuded alveolar epithelium. To test this hypothesis, we developed a ‘collagen drop’ cell migration assay where an aggregated population of AECs were resuspended in a drop of collagen which was ‘dropped’ onto a surface coated with Fibronectin, Lumican, or Periostin. To provide an additional ‘positive’ bias to AEC migration the collagen drop contained 0.2% FBS whereas the external serum concentration was 20% (Figure 6A). Optimal cell migration was observed on either Fibronectin or Lumican coated surfaces at a concentration of 10 ng/ml (Fibronectin 27.7 ± 11.1 cells/mm vs. 6.7 ± 1.5 cells/mm (uncoated surface), p < 0.001; Lumican 30.7 ± 6.8 cells/mm vs. 5.7 ± 1.4 cells/mm (uncoated surface), p < 0.001) (Figure 6B, 6C). On the other hand, Periostin did not stimulate AEC migration (Figure 6B, 6C). Taken together this indicates that Fibronectin and Lumican stimulated AEC wound repair as both soluble factors and as a substrate component whereas Periostin stimulated AEC wound repair as a soluble factor only.
Human mesenchymal stem cells (hMSC) are in current clinical trials for incurable diseases including osteogenesis imperfecta, graft-versus-host disease, chronic ischemic heart disease, and chronic obstructive pulmonary disease (http://www.clinicaltrials.gov) and are the focus of many other clinical applications. Studies on animal pulmonary fibrosis models demonstrate that intravenous and endotracheal administration of MSCs attenuate lung injury and fibrosis suggesting a potential clinical application of MSCs for the treatment of IPF [16, 17, 31]. However, the mechanism of MSC-mediated amelioration of pulmonary fibrosis is not clear and an active participation of MSCs through differentiation into AEC and lung regeneration is under debate [16, 32]. Bleomycin-induced mouse lung fibrosis models have demonstrated an MSC stimulated reduction in pulmonary fibrosis via inhibition of pro-fibrotic cytokines TNF-α and IL-1 through a paracrine mechanism . Furthermore, rat models of pulmonary emphysema demonstrated that MSCs reduce AEC apoptosis through paracrine mechanism via up-regulation of anti-apoptotic Bcl-2 gene . Here we demonstrate that in response to injury, hMSC display site-specific migration into AEC wounds; this observation has also been noted by others in animal lung injury models [16, 17]. Coupled to this hMSC migration, we also demonstrate that in response to SF-MSC CM, AEC and SAEC migration and wound repair occur with distinct trace serum augmentation requirements. We also provide evidence supporting specific hMSC-secreted paracrine components for effective alveolar and small airway epithelial wound repair.
hMSC secret a myriad of proteins that include growth factors, cytokines and ECM proteins [19, 20]. Many of these secretory proteins are biologically active with anti-inflammatory, anti-fibrotic and immunomodulatory functions [21, 22]. Previous and current studies are mostly focused on evaluation of MSC-secreted growth factors and their effects on tissue repair. Here, in line with others, our mass spectrometry-mediated hMSC secretome analyses indicate the presence of a high abundance of ECM/matricellular protein components with diverse biological activities on wound healing and tissue repair [20, 23]. Fibronectin (a multifunctional glycoprotein), Lumican (collagen-binding keratin sulfate proteoglycan), Periostin (matricellular N-glycoprotein), and IGFBP-7 (IGF-I, -II low affinity binding protein) were identified as major components of SF-MSC CM through high peptide counts and ion score confidence intervals (Table 1). Data supportive of a role for these factors in alveolar wound repair is relatively scarce though implied in previous studies. Fibronectin upregulation is implicated in abdominal wall, corneal, and skin in vivo and ex vivo wound repair and migration where values ranging from 100 ng/ml to 60 μg/ml of Fibronectin have been evaluated [35–39]. In vitro models including corneal epithelial cells, corneal fibroblasts, keratinocyte, dermal fibroblast, nasal airway epithelial cells, gingival fibroblast, and SAEC have further demonstrated that fibronectin stimulated wound repair and cell migration as either soluble factor or substrate component frequently through integrin signaling activation [40–45].
Lumican, a small leucine-rich proteoglycan (SLRP) family member, is a major component of the proteoglycan-based ECM. Lumican displays a heterogeneous, diffuse, staining profile in the alveolar walls and peripheral regions of adult human lung and its sub-epithelial deposition is implicated in airway remodeling and counteracting the severity of asthma [46, 47]. In vivo and ex vivo studies indicate that Lumican is essential for corneal epithelial cell, skin, and oral mucosa wound repair and promotion of chemotactic migration [48–51]. In vitro migration and wound healing of corneal epithelial cells was also induced by Lumican [52, 53]. Circulating plasma and cellular Fibronectin concentrations (300 μg/ml and 2.46 μg/ml, respectively) are substantially in excess of those required to induce wound repair and migration in our, and previously described (see above), in vitro models whereas physiological levels of Lumican are yet to be defined . In support and extension of these previous reports we have now demonstrated that both Fibronectin and Lumican facilitated AEC and SAEC wound repair as soluble factors (with trace serum supplementation for AEC only) and migration of AEC as a substrate component.
Periostin (or OSF-2, Osteoblast Specific Factor-2) is a matricellular protein with a poorly defined role in wound repair and a physiological serum level of approximately 39 ng/ml [55, 56]. In vivo studies revealed an association with fracture healing, wound-derived blood vessels, acute myocardial infarction response, skin wounds, and ligament repair [57–62]. In addition to those above low levels of Periostin expression are common in normal lung while high levels of Periostin are detected in IPF lungs and patient serum although the role of this protein in the pathogenesis of lung fibrosis has not been clarified . A relationship between Periostin and wound repair across multiple tissues is immediately apparent though little is known, at this time, of mechanism of action. A solitary report describes exogenous overexpression of Periostin in A549 cells, as used in our study, which enhanced both proliferation and migration in routine culture . We have herein reported that Periostin has a role in AEC and SAEC wound repair and migration as a soluble factor and identified a putative hMSC source of wound associated Periostin.
IGFBP-7 (also known as IGFBP-rP1) is an IGFBP-related protein (IGFBP-rPs) superfamily member. IGFBP-rPs have less binding affinity to IGF (insulin growth factor) and are involved in diverse biological activities in an IGF-independent manner . IGFBP-rP2 (CTGF (connective tissue growth factor)), another IGFBP-rP family member, plays a critical role during fibrogenesis in IPF [65, 66]. However, the role of IGFBP-7, which has a normal serum concentration of 33 ng/ml , in pulmonary fibrosis is unknown. IGFBP-7 is up-regulated in the fibrotic regions of IPF lung tissue as well as in isolated IPF fibroblasts though absent from controls . Here we have demonstrated that recombinant human IGFBP-7 significantly increased human primary SAEC wound repair when applied in serum-free basal media, whereas AEC were non-responsive to this protein. The mechanism behind these divergent responses remains to be clarified. The development of transferable and accessible primary human AEC cultures (which replicate in vivo characteristics; i.e. monolayer formation) will be necessary before clarification can be achieved. However at this time we cannot preclude the possibility that the distinct response is due tissue source or phenotypic background of the AEC and SAEC used in this study. However this distinction in response provides strong support for broad therapeutic applicability across multiple clinical applications for the hMSC secretome. Characterization of these cell-specific responses will underpin the continuing development of the stem cell-driven regenerative medicine industry.
The protein composition of ECM is variable, tissue specific, and provides essential scaffold and biochemical signals required for cell growth, tissue homeostasis, development and wound repair [55, 69]. Our in vitro AEC wound repair data encouraged us to investigate the substrate roles of Fibronectin, Lumican and Periostin on AEC migration. The in vitro scratch wound repair system is not suitable to test the effectiveness of individual substrate components as the wounding process would disrupt the protein coating. We developed a novel ‘collagen drop’ cell migration assay to evaluate individual substrate component capacity to support or inhibit migration. Normal basement membrane architecture provides a favourable substrate for AEC migration whereas disrupted alveolar basement membrane and aberrant ECM remodeling play a crucial role in the abrogation of alveolar re-epithelialisation in pulmonary fibrosis . Data from our ‘collagen drop’ cell migration assay has identified that both Fibronectin and Lumican are supportive of cell migration as substrate component. From consideration of the data obtained from wound repair and collagen drop assays we suggest a putative dual role (as topical and substrate components) of Fibronectin and Lumican, and a topical role of Periostin on alveolar epithelial cell migration and wound repair. Fibronectin, Lumican and Periostin have diverse biological effects on various cell types depending on their interactions with different receptor families, such as integrins, receptor tyrosine kinases (RTKs) and IGF-receptor [69–73]. It can be speculated that an individual candidate protein may stimulate different receptors depending on the mode of application with the potential to trigger different outcomes. Here our two different assay systems illustrated the effects of Periostin on AEC migration operated in an administration-dependent fashion. Further elucidation of hMSC secretory proteins and their interactions with target receptors in alveolar epithelial wound repair will provide a clear understanding in hMSC-mediated alveolar injury repair and regeneration.
These data provide insight into potential hMSC paracrine influences on epithelial wound repair during alveolar injury repair. Aberrant alveolar re-epithelialisation is believed to be one of the major contributing factors for uncontrolled fibrogenesis in IPF . Therefore, stimulation of re-epithelialisation within the alveolar regions could be a potential active vector for alleviation of the pro-fibrogenic processes as a curative therapeutic measure for IPF. Previous animal model-based studies demonstrated that MSC-paracrine factors attenuate pulmonary fibrosis through modulation of inflammation, suppression of fibrogenesis and stimulation of angiogenesis [19, 20, 31, 33]. Here, we have demonstrated the efficacious influence of the hMSC secretome in the modulation of alveolar and small airway epithelial cell dynamics resulting in stimulation of wound repair. In-depth understanding of the humoral mechanisms of hMSCs in epithelial wound repair and regeneration will provide extended therapeutic options for clinical application of hMSC or their secretory products for fibrotic lung diseases, such as IPF.
This study was supported by a joint award through Medical Research Council Dorothy Hodgkin Postgraduate Award and the Chest Fund Charity, University Hospital of North Staffordshire.
- Deb A, Wang S, Skelding KA, Miller D, Simper D, Caplice NM: Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients. Circulation. 2003, 107: 1247-1249. 10.1161/01.CIR.0000061910.39145.F0.PubMedView ArticleGoogle Scholar
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.PubMedView ArticleGoogle Scholar
- Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD: Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002, 105: 93-98. 10.1161/hc0102.101442.PubMedView ArticleGoogle Scholar
- Dezawa M, Kanno H, Hoshino M, Cho H, Matsumoto N, Itokazu Y, Tajima N, Yamada H, Sawada H, Ishikawa H, Mimura T, Kitada M, Suzuki Y, Ide C: Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest. 2004, 113: 1701-1710.PubMedPubMed CentralView ArticleGoogle Scholar
- Zeng R, Wang LW, Hu ZB, Guo WT, Wei JS, Lin H, Sun X, Chen LX, Yang LJ: Differentiation of human bone marrow mesenchymal stem cells into neuron-like cells in vitro. Spine (Phila Pa 1976). 2011, 36: 997-1005. 10.1097/BRS.0b013e3181eab764.View ArticleGoogle Scholar
- Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K, Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A, Hamada H, Niitsu Y: Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood. 2005, 106: 756-763. 10.1182/blood-2005-02-0572.PubMedView ArticleGoogle Scholar
- Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC, Fine A: Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development. 2001, 128: 5181-5188.PubMedGoogle Scholar
- Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, Marshak DR, Flake AW: Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000, 6: 1282-1286. 10.1038/81395.PubMedView ArticleGoogle Scholar
- Ma N, Gai H, Mei J, Ding FB, Bao CR, Nguyen DM, Zhong H: Bone marrow mesenchymal stem cells can differentiate into type II alveolar epithelial cells in vitro. Cell Biol Int. 2011, 35: 1261-1266. 10.1042/CBI20110026.PubMedView ArticleGoogle Scholar
- Akram KM, Samad S: Spiteri M. 2012, Forsyth NR: Mesenchymal Stem Cell Therapy and Lung Diseases. Adv Biochem Eng BiotechnolGoogle Scholar
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ: ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011, 183: 788-824. 10.1164/rccm.2009-040GL.PubMedView ArticleGoogle Scholar
- Kaminski N: Microarray analysis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003, 29: S32-S36.PubMedView ArticleGoogle Scholar
- Selman M, King TE, Pardo A: American Thoracic Society, European Respiratory Society, American College of Chest Physicians: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001, 134: 136-151.PubMedView ArticleGoogle Scholar
- Strieter RM: Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest. 2005, 128: 526S-532S. 10.1378/chest.128.5_suppl_1.526S.PubMedView ArticleGoogle Scholar
- Harrison JH, Lazo JS: High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther. 1987, 243: 1185-1194.PubMedGoogle Scholar
- Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003, 100: 8407-8411. 10.1073/pnas.1432929100.PubMedPubMed CentralView ArticleGoogle Scholar
- Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL: Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005, 33: 145-152. 10.1165/rcmb.2004-0330OC.PubMedPubMed CentralView ArticleGoogle Scholar
- Weiss DJ, Finck C: Embryonic stem cells and repair of lung injury. Mol Ther. 2010, 18: 460-461. 10.1038/mt.2010.8.PubMedPubMed CentralView ArticleGoogle Scholar
- Chen L, Tredget EE, Wu PY, Wu Y: Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008, 3: e1886-10.1371/journal.pone.0001886.PubMedPubMed CentralView ArticleGoogle Scholar
- Estrada R, Li N, Sarojini H, An J, Lee M, Wang E: Secretome from mesenchymal stem cells induces angiogenesis via Cyr61. J Cell Physiol. 2009, 219: 563-571. 10.1002/jcp.21701.PubMedPubMed CentralView ArticleGoogle Scholar
- Meirelles Lda S, Fontes AM, Covas DT, Caplan AI: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009, 20: 419-427. 10.1016/j.cytogfr.2009.10.002.PubMedView ArticleGoogle Scholar
- Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007, 110: 3499-3506. 10.1182/blood-2007-02-069716.PubMedView ArticleGoogle Scholar
- Walter MN, Wright KT, Fuller HR, MacNeil S, Johnson WE: Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays. Exp Cell Res. 2010, 316: 1271-1281. 10.1016/j.yexcr.2010.02.026.PubMedView ArticleGoogle Scholar
- Nguyen BK, Maltais S, Perrault LP, Tanguay JF, Tardif JC, Stevens LM, Borie M, Harel F, Mansour S, Noiseux N: Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J Cardiovasc Transl Res. 2010, 3: 547-558. 10.1007/s12265-010-9171-0.PubMedView ArticleGoogle Scholar
- D’Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC: Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci. 2004, 117: 2971-2981. 10.1242/jcs.01103.PubMedView ArticleGoogle Scholar
- Wimpenny I, Hampson K, Yang Y, Ashammakhi N, Forsyth NR: One-step recovery of marrow stromal cells on nanofibers. Tissue Eng Part C Methods. 2010, 16: 503-509. 10.1089/ten.tec.2009.0128.PubMedView ArticleGoogle Scholar
- Geiser T, Jarreau PH, Atabai K, Matthay MA: Interleukin-1beta augments in vitro alveolar epithelial repair. Am J Physiol Lung Cell Mol Physiol. 2000, 279: L1184-L1190.PubMedGoogle Scholar
- Plumb JA, Milroy R, Kaye SB: Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989, 49: 4435-4440.PubMedGoogle Scholar
- Akram KM, Lomas NJ: Spiteri MA. 2012, Forsyth NR: Clara cells inhibit alveolar epithelial wound repair via TRAIL-dependent apoptosis. Eur Respir JGoogle Scholar
- Atabai K, Ishigaki M, Geiser T, Ueki I, Matthay MA, Ware LB: Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms. Am J Physiol Lung Cell Mol Physiol. 2002, 283: L163-L169.PubMedView ArticleGoogle Scholar
- Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, Boyd R, Trounson A: Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol. 2009, 175: 303-313. 10.2353/ajpath.2009.080629.PubMedPubMed CentralView ArticleGoogle Scholar
- Neuringer IP, Randell SH: Lung stem cell update: promise and controversy. Monaldi Arch Chest Dis. 2006, 65: 47-51.PubMedGoogle Scholar
- Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG: Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A. 2007, 104: 11002-11007. 10.1073/pnas.0704421104.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhen G, Liu H, Gu N, Zhang H, Xu Y, Zhang Z: Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci. 2008, 13: 3415-3422.PubMedView ArticleGoogle Scholar
- Cheng CY, Martin DE, Leggett CG, Reece MC, Reese AC: Fibronectin enhances healing of excised wounds in rats. Arch Dermatol. 1988, 124: 221-225. 10.1001/archderm.1988.01670020039014.PubMedView ArticleGoogle Scholar
- Fujikawa LS, Foster CS, Harrist TJ, Lanigan JM, Colvin RB: Fibronectin in healing rabbit corneal wounds. Lab Invest. 1981, 45: 120-129.PubMedGoogle Scholar
- Grinnell F, Billingham RE, Burgess L: Distribution of fibronectin during wound healing in vivo. J Invest Dermatol. 1981, 76: 181-189. 10.1111/1523-1747.ep12525694.PubMedView ArticleGoogle Scholar
- Kwon AH, Qiu Z, Hiraon Y: Effect of plasma fibronectin on the incisional wound healing in rats. Surgery. 2007, 141: 254-261. 10.1016/j.surg.2006.06.036.PubMedView ArticleGoogle Scholar
- Nishida T, Nakagawa S, Awata T, Ohashi Y, Watanabe K, Manabe R: Fibronectin promotes epithelial migration of cultured rabbit cornea in situ. J Cell Biol. 1983, 97: 1653-1657. 10.1083/jcb.97.5.1653.PubMedView ArticleGoogle Scholar
- Dean JW, Blankenship JA: Migration of gingival fibroblasts on fibronectin and laminin. J Periodontol. 1997, 68: 750-757. 10.1902/jop.1922.214.171.1240.PubMedView ArticleGoogle Scholar
- Herard AL, Pierrot D, Hinnrasky J, Kaplan H, Sheppard D, Puchelle E, Zahm JM: Fibronectin and its alpha 5 beta 1-integrin receptor are involved in the wound-repair process of airway epithelium. Am J Physiol. 1996, 271: L726-L733.PubMedGoogle Scholar
- Hocking DC, Chang CH: Fibronectin matrix polymerization regulates small airway epithelial cell migration. Am J Physiol Lung Cell Mol Physiol. 2003, 285: L169-L179.PubMedView ArticleGoogle Scholar
- Nishida T, Nakamura M, Mishima H, Otori T: Interleukin 6 promotes epithelial migration by a fibronectin-dependent mechanism. J Cell Physiol. 1992, 153: 1-5. 10.1002/jcp.1041530102.PubMedView ArticleGoogle Scholar
- Schmidinger G, Hanselmayer G, Pieh S, Lackner B, Kaminski S, Ruhswurm I, Skorpik C: Effect of tenascin and fibronectin on the migration of human corneal fibroblasts. J Cataract Refract Surg. 2003, 29: 354-360. 10.1016/S0886-3350(02)01609-7.PubMedView ArticleGoogle Scholar
- Yamada KM: Fibronectin peptides in cell migration and wound repair. J Clin Invest. 2000, 105: 1507-1509. 10.1172/JCI10119.PubMedPubMed CentralView ArticleGoogle Scholar
- Dolhnikoff M, Morin J, Roughley PJ, Ludwig MS: Expression of lumican in human lungs. Am J Respir Cell Mol Biol. 1998, 19: 582-587.PubMedView ArticleGoogle Scholar
- Pini L, Hamid Q, Shannon J, Lemelin L, Olivenstein R, Ernst P, Lemiere C, Martin JG, Ludwig MS: Differences in proteoglycan deposition in the airways of moderate and severe asthmatics. Eur Respir J. 2007, 29: 71-77.PubMedView ArticleGoogle Scholar
- Honardoust D, Eslami A, Larjava H, Hakkinen L: Localization of small leucine-rich proteoglycans and transforming growth factor-beta in human oral mucosal wound healing. Wound Repair Regen. 2008, 16: 814-823. 10.1111/j.1524-475X.2008.00435.x.PubMedView ArticleGoogle Scholar
- Lee S, Bowrin K, Hamad AR, Chakravarti S: Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to beta2 integrin. J Biol Chem. 2009, 284: 23662-23669. 10.1074/jbc.M109.026229.PubMedPubMed CentralView ArticleGoogle Scholar
- Saika S, Shiraishi A, Liu CY, Funderburgh JL, Kao CW, Converse RL, Kao WW: Role of lumican in the corneal epithelium during wound healing. J Biol Chem. 2000, 275: 2607-2612. 10.1074/jbc.275.4.2607.PubMedPubMed CentralView ArticleGoogle Scholar
- Yeh JT, Yeh LK, Jung SM, Chang TJ, Wu HH, Shiu TF, Liu CY, Kao WW, Chu PH: Impaired skin wound healing in lumican-null mice. Br J Dermatol. 2010, 163: 1174-1180. 10.1111/j.1365-2133.2010.10008.x.PubMedView ArticleGoogle Scholar
- Seomun Y, Joo CK: Lumican induces human corneal epithelial cell migration and integrin expression via ERK 1/2 signaling. Biochem Biophys Res Commun. 2008, 372: 221-225. 10.1016/j.bbrc.2008.05.014.PubMedView ArticleGoogle Scholar
- Yeh LK, Chen WL, Li W, Espana EM, Ouyang J, Kawakita T, Kao WW, Tseng SC, Liu CY: Soluble lumican glycoprotein purified from human amniotic membrane promotes corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2005, 46: 479-486. 10.1167/iovs.04-1014.PubMedPubMed CentralView ArticleGoogle Scholar
- Ylatupa S, Haglund C, Mertaniemi P, Vahtera E, Partanen P: Cellular fibronectin in serum and plasma: a potential new tumour marker?. Br J Cancer. 1995, 71: 578-582. 10.1038/bjc.1995.112.PubMedPubMed CentralView ArticleGoogle Scholar
- Hamilton DW: Functional role of periostin in development and wound repair: implications for connective tissue disease. J Cell Commun Signal. 2008, 2: 9-17. 10.1007/s12079-008-0023-5.PubMedPubMed CentralView ArticleGoogle Scholar
- Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, Ohshima K, Shiraishi H, Uchida M, Ono J, Ohta S, Kato S, Izuhara K, Aizawa H: Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 2011, 37: 1119-1127. 10.1183/09031936.00059810.PubMedView ArticleGoogle Scholar
- Chamberlain CS, Brounts SH, Sterken DG, Rolnick KI, Baer GS, Vanderby R: Gene profiling of the rat medial collateral ligament during early healing using microarray analysis. J Appl Physiol. 2011, 111: 552-565. 10.1152/japplphysiol.00073.2011.PubMedPubMed CentralView ArticleGoogle Scholar
- Jackson-Boeters L, Wen W, Hamilton DW: Periostin localizes to cells in normal skin, but is associated with the extracellular matrix during wound repair. J Cell Commun Signal. 2009, 3: 125-133. 10.1007/s12079-009-0057-3.PubMedPubMed CentralView ArticleGoogle Scholar
- Nakazawa T, Nakajima A, Seki N, Okawa A, Kato M, Moriya H, Amizuka N, Einhorn TA, Yamazaki M: Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J Orthop Res. 2004, 22: 520-525. 10.1016/j.orthres.2003.10.007.PubMedView ArticleGoogle Scholar
- Nishiyama T, Kii I, Kashima TG, Kikuchi Y, Ohazama A, Shimazaki M, Fukayama M, Kudo A: Delayed re-epithelialization in periostin-deficient mice during cutaneous wound healing. PLoS One. 2011, 6: e18410-10.1371/journal.pone.0018410.PubMedPubMed CentralView ArticleGoogle Scholar
- Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, Saga Y, Fukayama M, Sata M, Kudo A: Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med. 2008, 205: 295-303. 10.1084/jem.20071297.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhou HM, Wang J, Elliott C, Wen W, Hamilton DW, Conway SJ: Spatiotemporal expression of periostin during skin development and incisional wound healing: lessons for human fibrotic scar formation. J Cell Commun Signal. 2010, 4: 99-107. 10.1007/s12079-010-0090-2.PubMedPubMed CentralView ArticleGoogle Scholar
- Hong L, Sun H, Lv X, Yang D, Zhang J, Shi Y: Expression of periostin in the serum of NSCLC and its function on proliferation and migration of human lung adenocarcinoma cell line (A549) in vitro. Mol Biol Rep. 2010, 37: 2285-2293. 10.1007/s11033-009-9721-1.PubMedView ArticleGoogle Scholar
- Hwa V, Oh Y, Rosenfeld RG: The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999, 20: 761-787. 10.1210/er.20.6.761.PubMedGoogle Scholar
- Allen JT, Knight RA, Bloor CA, Spiteri MA: Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 1999, 21: 693-700.PubMedView ArticleGoogle Scholar
- Pan LH, Yamauchi K, Uzuki M, Nakanishi T, Takigawa M, Inoue H, Sawai T: Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J. 2001, 17: 1220-1227. 10.1183/09031936.01.00074101.PubMedView ArticleGoogle Scholar
- Kutsukake M, Ishihara R, Momose K, Isaka K, Itokazu O, Higuma C, Matsutani T, Matsuda A, Sasajima K, Hara T, Tamura K: Circulating IGF-binding protein 7 (IGFBP7) levels are elevated in patients with endometriosis or undergoing diabetic hemodialysis. Reprod Biol Endocrinol. 2008, 6: 54-54. 10.1186/1477-7827-6-54.PubMedPubMed CentralView ArticleGoogle Scholar
- Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA: Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011, 63: 783-794. 10.1002/art.30159.PubMedPubMed CentralView ArticleGoogle Scholar
- Frantz C, Stewart KM, Weaver VM: The extracellular matrix at a glance. J Cell Sci. 2010, 123: 4195-4200. 10.1242/jcs.023820.PubMedPubMed CentralView ArticleGoogle Scholar
- Edderkaoui M, Hong P, Lee JK, Pandol SJ, Gukovskaya AS: Insulin-like growth factor-I receptor mediates the prosurvival effect of fibronectin. J Biol Chem. 2007, 282 (37): 26646-26655. 10.1074/jbc.M702836200.PubMedView ArticleGoogle Scholar
- Veevers-Lowe J, Ball SG, Shuttleworth A, Kielty CM: Mesenchymal stem cell migration is regulated by fibronectin through α5β1-integrin-mediated activation of PDGFR-β and potentiation of growth factor signals. J Cell Sci. 2011, 124 (Pt 8): 1288-1300.PubMedPubMed CentralView ArticleGoogle Scholar
- Merline R, Schaefer RM, Schaefer L: The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal. 2009, 3 (3–4): 323-335.PubMedPubMed CentralView ArticleGoogle Scholar
- Yan W, Shao R: Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem. 2006, 281 (28): 19700-19708. 10.1074/jbc.M601856200.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.